Provisional Timed Program

• What is your definition of Personalized Medicine in Oncology, and how does this affect your future prosperity?
• Understand the vital aspects of development (including biomarkers) you need to consider
• Examine the actions which are required to deal with regulatory issues
• Commercialization: How to create effective sales and marketing strategies for personalized products and systems

Mark Smith
President,

Merck Serono Co., Ltd.

• How to bring a personalized product into development in Japan
• How to conduct the clinical program with a personalized product
• How to carry out the filing and approval process effectively
• Winning ways to collaborate with marketing during and after development

Dr Stephen Uden
Head of Oncology Development, Oncology Development,

Novartis Pharma K.K.

• How it is possible to provide safety / reliability and added value amongst generics and biosimilars in Oncology
• What kind of future development can be learned from Sandoz (a pioneer of biosimilars)?

• Learn about Sandoz’s R&D and production on a global scale – and the implications for your organization

Junichi Nakamichi
Country Head,

Sandoz K.K.

Issues in Oncology: from a 21st century clinical site's point of view

• How do Oncologists think about the costs / benefits of anti-cancer drugs?
• Why medical malpractice lawsuits happen?
• What kind of measurements are required to improve current situations in Oncology?

Kaoru Kubota 

Chief of Chemotherapy Division，Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases, and Oncology,

Nippon Medical School Hospital

• Understand what kind of common knowledge between each stakeholder will implementation of Personalized Medicine?
• How to create methods to overcome key challenges such as encouraging clinical trials in Japan Panel Facilitator:

• Jun Katsura, Director and Executive Officer, Vice President, Oncology & Anaesthesia / Critical Care, AstraZeneca K. K.

• Mark Smith, President, Merck Serono Co., Ltd.
• Pascal Rigaudy, Corporate Officer, Head of Oncology Business Unit, Oncology Business Unit, sanofi-aventis K.K.
• Dr Stephen Uden, Head of Oncology Development, Oncology Development,
  Novartis Pharma K.K.
• Kaoru Kubota, Chief of Chemotherapy Division，Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases, and Oncology, Nippon Medical School Hospital
• Kenichi Tamiya, Deputy Director, Research and Development Division,
  Health Policy Bureau, Ministry of Health, Labour and Welfare

In accordance with government policy, admission to this panel discussion is free of charge; subject to capacity. Delegates to Oncology Japan 2011 will be automatically enrolled. If you are not registered for the conference but would like to attend this session, apply to kakahoshi@eyeforpharma.com

• How to combine the implementation of ‘information for proper use’ with sales activities

• Ways to promote multidisciplinary cancer care to establish uniform access to standardized cancer treatment regardless of area
• How to adjust your strategies with the movement towards Personalized Medicine

• Understand the details of Oncology MR’s activities
• Why are patient-focused activities a core factor for Oncology MRs?
• Learn about effective sales coaching tips specifically designed for Oncology MRs

Akira Kanda
Senior Manager, Training, Sales Department, Sales & Marketing,

Celgene K.K.

• What are the appropriate roles of Medical and Sales departments in Oncology?
• How to create effective sales strategies that make full use of the medical department

Toshitaka Taniguchi
Business Operation Director, Oncology & Anaesthesia /Critical care,

AstraZeneca K.K.

• What are the differences between Japanese and other Asian Oncology markets?
• Learn about where Japanese companies can find new sources of growth in Oncology
• How can you improve the preparation of your launch readiness when the drug lag is shortened?

Pierre Wan,
Head of Marketing, Marketing Department, Oncology Business Unit,

Novartis Pharma K.K.

• Determine the actual differences between Oncology and other disease area from a sales and marketing point of view
• Is creating a message for Oncology products different from other disease areas?
• How to create effective strategies around the relationships with stakeholders in the Japanese Oncology market

• Find out how Yakult created unique marketing strategies that utilized their own name value
• Hear how Yakult prepared for the market development and Adverse Event (AE) management for the product launch of ELPLAT

• Cancer incidence trends in Japan: a useful comparison with other countries.

• What kinds of data sources are available in Japan?  How you can best utilize the data
• Understand the different sources when assessing cancer patient populations

Ayako Muramatsu
General Manager, Market Assessment Business Unit,

Synix Inc.

• Why the measurement for adverse events is essential to improve cancer treatments and in particular to gain life prolongation
• Learn how the measurement of individual regimens is important, since combination chemotherapies and adjuvant therapies with other anti-cancer drugs are often used in Oncology.
• Understand the importance of finding solutions for current package inserts that mainly feature the safety information of the drug when it is used as monotherapy

•  Understand the principle and practice of critical path research – based on case studies of Cancer Translational research program (2004 – 2008) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT)　
• How to develop the translational research centre and create R&D pipelines
• Hear how to create the grand design of conquering cancer – the innovation platform of industry, government and academia and the management of the clinical science program　

• Hear the case studies of online communities for cancer patients support that have been successful in overseas
• What can Pharmaceutical companies do with social media to support cancer patients and their families
• Understand current trends and issues of operational environment in online communities for cancer patients in Japan

• What kinds of support are patients are looking for to improve their QOL?
• Learn what kind of activities that cancer specialist nurses and other nurses are working on to provide palliative care from early stage

• What kind of support are cancer patients are actually looking for?
• As a Team Healthcare, what kind of support should be provided to improve patient’s QOL?
• What kind of practical methods are needed to provide correct information about anti-cancer drugs and cancer treatment?

• Susumu Adachi, M.D., Senior Director, Oncology Business Unit, Eli Lilly Japan K.K.

• Andreas Tsukada , BU Head, Executive Management Team, Oncology Business Unit, Merck Serono Co., Ltd.
• Shigeo Horie, Professor and Chairman, Department of Urology, Teikyo University
• Hisanaga Nomura, Chief & Board Certified Oncology Pharmacy Specialist, Department of Pharmacy, Kyorin University Hospital
• Megumi Umeda, President, Palliative Care Partners Co., Ltd.
• Yoshiyuki Majima, Director, Pancreatic Cancer Action Network Japan